Patents by Inventor Toshiya Yamagishi

Toshiya Yamagishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STATOR
    Publication number: 20240146140
    Abstract: In this stator, lead wire extended portions and a power wire extended portion are extended from a resin portion by an extended portion separating portion such that the lead wire extended portions are separated from the power wire extended portion by distances that are greater than a maximum value of the width of clearance between an end-side portion of the lead wire extended portion and a facing portion located next to the end-side portion, the resin portion being provided so as to cover lead wire portions and a power wire portion.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 2, 2024
    Applicants: AISIN CORPORATION, TOYOTA JIDOSHA KABUSHIKI KAISHA, DENSO CORPORATION
    Inventors: Toshiya SUGIYAMA, Munehiro TAKAHASHI, Keisuke KIMURA, Ken TAKEDA, Takahito NOZAWA, Takashi MATSUMOTO, Yoshitada YAMAGISHI, Katsuhide KITAGAWA, Hajime KATO
  • Antibody to hepatocyte growth factor activator inhibitor-1 and use thereof
    Patent number: 7087391
    Abstract: A hybridoma is selected that produces a monoclonal antibody exhibiting high reactivity to soluble hepatocyte growth factor activator inhibitor-1 (soluble HAI-1), the target monoclonal antibody is prepared from culture supernatant of the obtained hybridoma, and by using the antibody soluble HAI-1 is measured.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: August 8, 2006
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Toshiya Yamagishi, Daiji Naka, Kazuhiro Nagaike
  • Antibody to hepatocyte growth factor activator inhibitor-1 and use thereof
    Publication number: 20030064420
    Abstract: A hybridoma is selected that produces a monoclonal antibody exhibiting high reactivity to soluble hepatocyte growth factor activator inhibitor-1 (soluble HAT-1), the target monoclonal antibody is prepared from culture supernatant of the obtained hybridoma, and by using the antibody soluble HAI-1 is measured.
    Type: Application
    Filed: May 24, 2002
    Publication date: April 3, 2003
    Inventors: Toshiya Yamagishi, Daiji Naka, Kazuhiro Nagaike